1. Introduction {#s0005}
===============

*Dientamoeba fragilis* was first described in 1918 as a binucleated, unflagellated protozoan that inhabits the large intestine ([@bb0100]). On electron microscopy, it has been reclassified as an amoeba‐flagellate rather than an amoeba ([@bb0030]). It has a worldwide distribution in both urban and rural areas with infection rates ranging from 0.5% to 16%, where higher rates were reported in outbreaks and associated to the lack of personal hygiene ([@bb0080]). In adults, asymptomatic colonization is present in 75‐85% of individuals affected by the parasite while in children; disease develops in as many as 90% of those colonized ([@bb0045]). Similar to some other parasites (*e.g.*, *Giardia lamblia*, *Cyclospora cayetanensis*, *Cryptosporidium spp.*), the parasite *D. fragilis* has been showed to cause disease in humans regardless of their immune status. Abdominal pain/discomfort and diarrhea are the symptoms most often described in patients harboring *Dientamoeba*. Other symptoms may include fecal urgency, vomiting, nausea, anorexia, weight loss and fever ([@bb0050], [@bb0145], [@bb0185]). The parasite is increasingly recognized as a relatively common cause of human diarrhea and long-term chronic infections is commonly observed in infected patients ([@bb0185]). *Dientamoeba fragilis* is often associated with other intestinal parasites. A study investigated 1497 confirmed *D. fragilis* cases and found coinfections with *Blastocystis* spp. in 40.3%, with *Endolimax nana* in 24%, and with *Entamoeba coli*, *G. lamblia* and *Entrobius vermicularis* in 6, 5.7 and 5% of the cases, respectively ([@bb0005]).

*D. fragilis* cells tend to infect the mucosal crypts of the large intestine from the caecum to the rectum, which is located close to the mucosal epithelium ([@bb0125]). In addition, this parasite is not known to be invasive and does not cause cellular damage. It may elicit an eosinophilic inflammatory response in the colonic mucosa. Thus, symptoms are related to the irritation of the superficial colonic mucosal, and it has been reported to be associated with marked peripheral eosinophilia ([@bb0085]).

Despite the evidence supporting its pathogenic nature ([@bb0180]), it is apparent that a degree of uncertainty still surrounds the pathogenic potential of *D. fragilis* ([@bb0005], [@bb0010]). To be recognized as a true pathogen Koch\'s postulate must be fulfilled for *Dientamoeba* as a cause of gastrointestinal illness. Studies conducted to investigate the biology of this parasite are limited by methods of *in vitro* cultivation, with difficulties in establishment of long-term cultures. It is commonly observed that *D. fragilis* grows *in vitro* for only few subcultures before dying out ([@bb0035], [@bb0135]). Moreover, the lack of an animal model for dientamoebiasis hinders the ability to demonstrate its pathogenicity ([@bb0015]). However, recently few experimental studies have been carried out ([@bb0140], [@bb0060]). This study aimed to investigate the suitability of mice as an animal model for experimental *D. fragilis* infection, and to determine the required infective dose. In addition, we studied the pathological changes caused by *D. fragilis* infection in experimentally-challenged mice.

2. Subjects and methods {#s0010}
=======================

2.1. Isolation of *D. fragilis* {#s0015}
-------------------------------

The study was conducted from September 2015 to February 2016, in the Parasitology Department, Faculty of Medicine, Suez Canal University, Ismailia. Fecal specimens were collected from patients seeking medical care for different gastrointestinal complaints such as acute or chronic intermittent diarrhea, or diarrhea alternating with constipation, with or without abdominal pain and attending Outpatient Clinics of Suez Canal University and General Hospitals (Ismailia, Egypt). Fresh stool specimens were immediately examined microscopically by direct smear and Lugol\'s iodine for detection of *D. fragilis* and to exclude other intestinal parasites followed by formalin ethyl acetate concentration technique ([@bb0070]). Positive samples for *D. fragilis* were further stained with 10% Giemsa stain ([@bb0045]). Modified acid-fast and trichrome stains were performed to exclude infection of patients with other parasites *e.g. Cryptosporidium*, *Cyclospora*, *Cystoisospora* and *Microsporidium* spp. ([@bb0070]). Culture for common enteric bacterial pathogens was done to exclude them ([@bb0130]). Culture on Jones\' media without rice starch was done to exclude infection with *Blastocystis* spp. Positive samples for *D. fragilis* were cultivated in the modified Boeck and Drbohlav (MBD) medium supplemented with antibiotics ([@bb0165]). The culture was incubated at 37°C for 96h. Each day, the sediment of the culture tubes was examined by light microscopy with × 40 objectives for trophozoites. Daily count of the number of *D. fragilis* trophozoites was done using a Neubauer chamber to adjust the inoculation dose to 10^3^, 10^5^ and 4 × 10^6^ *D. fragilis*/0.5 ml culture medium.

2.2. Experimental animal infection {#s0020}
----------------------------------

Throughout the study, thirty-two 5--6weeks old immune-competent albino Balb/c mice, weighted 25--30 g, were purchased from the Veterinary Medicine Animal Lab, Suez Canal University. Mice were housed independently in good ventilated, filter-top cages and provided sterile rodent chow and water *ad libitum*. The cage bedding was changed every day to avoid and reduce the potential for fecal contamination occurring during the experiment. The animals were maintained in animal house at the faculty of Medicine, Suez Canal University at 25°C, and with a relative humidity of 40--60%.The mice were confirmed to be parasite-free by screening for several days by light microscopy, modified acid-fast and trichrome stain fecal smears for protozoa prior to infection with *D. fragilis*. Mice were randomly divided into four groups. The first three groups were inoculated with *D. fragilis* harvested from 4day-old cultures, at different doses: 10^3^, 10^5^, and 4×10^6^ *D. fragilis* trophozoites/0.5 ml culture medium given orally to G1, G2 and G3, respectively. The fourth group G4 (uninfected control) was given parasite-free culture media (0.5 ml/mouse). Oral inoculation was performed *via* 18G ball-tipped feeding needle attached to 1 ml syringe. All mice were monitored daily for weight loss, presence of loose stool or mucous in stool, lethargy and fur loss from day 1 to day 14 post inoculation. All mice were euthanized 2weeks post-inoculation. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed in this study.

2.3. Detection of *D. fragilis* in feces and intestine {#s0025}
------------------------------------------------------

Feces from all mice were examined microscopically by wet mount preparation at the 2nd, 4th and 8th day post-inoculation; also the intestinal content of sacrificed mice was examined. Culture on MBD media was done for negative specimens. In this case, cultures were considered negative if the organism was absent until the 7th day post-challenge.

To confirm the presence of *D. fragilis* in infected mice, genomic DNA was extracted from feces of all mice in the infected groups (G1--G3) using the QiaAMP DNA Stool Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions. DNA was kept frozen at − 20°C until PCR was performed. Then, conventional PCR targeting the SSUrRNA of *D. fragilis* was performed using the following primers; DF400 (5′TATCGGAGGTGGTAATGACC3 ′) and DF1250 (5′CATCTTCCTCCTGCTTAGACG3 ′). The reaction conditions were as follows: pre-denaturation at 94°C for 3 min, followed by 30 cycles of denaturation at 94°C for 1 min, annealing at 57°C for 1.5min, and extension at 72°C for 2min. DNA extracted from a *D. fragilis* positive sample was used as a positive control for PCR. A negative control PCR reaction mixture containing no input DNA was used. The amplified products were separated by electrophoresis in 1% agarose gels (Sigma, USA) in Tris--borate--EDTA buffer. Gels were stained with 0.5% ethidium bromide and photographed using an ultraviolet gel documentation system (UVP Biospectrum, UK) for the presence of specific bands at 870bp ([@bb0175]).

2.4. Histopathological examination {#s0030}
----------------------------------

Two weeks post infection mice were anesthetized and euthanized. Large intestine (colon and caecum) was assessed by naked eye, removed, preserved in 10% formalin, cut into three to five equal cross-sections and processed in paraffin blocks. Intestinal sections (4--8μm thickness) were stained with hematoxylin and eosin (H&E) for histopathological examination. Three sections were made from each tissue specimen (each separated by at least 500μm). Histopathological changes were scored blindly for each mouse. Degree of inflammation was scored from 0 to 4 (0, normal; 1, mucosal hyperplasia; 2, spotty infiltration by inflammatory cells not involving the entire thickness of the mucosa; 3, marked increase of inflammatory cells involving full thickness of mucosa; 4, marked increase of inflammatory cells in mucosa and submucosa, with tissue intact architecture ([@bb0090]).

3. Results {#s0035}
==========

3.1. Infectivity of *D. fragilis* {#s0040}
---------------------------------

The results obtained from mice inoculated orally with *D. fragilis* are summarized in [Table 1](#t0005){ref-type="table"}. During the period of the experiment, no infection occurred in the first group (G1), three mice became infected in G2 and the infection appeared on the fourth day post-inoculation, while all mice in G3 became infected 2 days post-inoculation. All mice in G3 showed loss of weight 2.5--3 g (about10% of the original body weight), decreased activity and diarrheic loose stool. While the three infected mice in G2 showed semi-formed stool without loss of weight.Table 1infectivity of *D. fragilis* to study groups through oral experimental infection.Table 1Studied groupInoculum[a](#tf0005){ref-type="table-fn"}N of mice/+ (%)G110^3^8/0 (0)G210^5^8/3 (37.5)G34 × 10^6^8/8 (100)[^1]

3.2. Detection of *D. fragilis* in stools and intestinal contents {#s0045}
-----------------------------------------------------------------

By direct examination of stool samples both trophozoite and presumptive cyst stages were detected in infected mice ([Fig. 1](#f0005){ref-type="fig"}).The average number of *D. fragilis* (trophozoite & presumptive cyst forms)/high power field (HPF) in the stool of the infected mice in each of the infected groups is shown in [Fig. 2](#f0010){ref-type="fig"}. Culture in MBD media was performed for positive stool samples to confirm the presence of the parasite. The stool samples and intestinal contents of all mice in G1 and the five mice in G2 which were microscopically negative were cultivated in MBD media and examined for 7days but no growth was detected. All infected mice with *D. fragilis* were confirmed by PCR through detection of the 870bp band targeting the SSUrRNA ([Fig. 3](#f0015){ref-type="fig"}).Fig. 1*D. fragilis* trophozoite irregular and rounded forms in wet mount (a -- c), irregular form showing inclusions of rice (d), Giemsa-stained trophozoites binucleated (e) and uninucleated (f), trichrome-stained trophozoite (g, h) and precyst (i), presumptive cyst by wet mount ( j) and iodine-stained (k), rounded form trophozoite in MBD culture.Fig. 1Fig. 2*Dientamoeba fragilis* intensity in direct stool smears of infected mice at different intervals post-inoculation. Data are expressed as average N/HPF.Fig. 2Fig. 3PCR products of *D. fragilis* isolated from stool samples of infected mice on 1% agarose gel stained with ethidium bromide. Lane M, molecular weight marker (100bp); lane 1, positive control; lane 2, negative control; lanes 3--5, infected animal samples with positive amplification of *D. fragilis* SSU rRNA at 870bp. 6 and 7 correspond to negative animal samples.Fig. 3

3.3. Histolopathological examination {#s0050}
------------------------------------

Naked eye examination of large intestine showed bloated, congested large intestine with loose diarrheic stool. Histopathological examination of G3 showed marked inflammatory infiltrates of mucosa and submucosa in colonic wall. In addition, the inflammatory infiltrates were composed mainly of eosinophils, lymphocytes and macrophages. There was also hyperplasia in colonic glands, edema in colonic submucosa, congested blood vessels in submucosa and hypertrophied muscle layer was evident. The degree of inflammation ranged between 4 and 5 degrees of inflammation. On the other hand, the histopathological examination of the three infected mice in G2 showed spotty inflammatory areas and mucosal hyperplasia and was scored as 1 to 2 degree of inflammation. *D. fragilis* did not infiltrate the colonic or caecal wall ([Fig. 4](#f0020){ref-type="fig"}).Fig. 4H&E sections of the large intestine of groups G3 (figures a, b, c, d and e) and G2 (figure f). a, b: marked inflammatory infiltrate of mucosa and submucosa in colonic wall (black arrow), with surface erosion (red arrow) (20 × and 10 ×, respectively), c: higher magnification of the inflammatory infiltrate showing eosinophils, lymphocytes and macrophages (40 ×), d: areas of colonic mucosa showing chronic inflammatory cell infiltrate (arrow head) within edematous stroma (red arrow) and congested blood vessels in submucosa (blue arrows) (10 ×), e: hyperplastic muscle layer (arrow head) is evident (10 ×), f: spotty infiltration by chronic inflammatory cells (black arrow) with hyperplastic colonic glands (20 ×).Fig. 4

4. Discussion {#s0055}
=============

*Dientamoeba fragilis*is a cosmopolitan occurring protozoan parasite found in human\'s mucosal crypts of the large intestine from caecum to rectum ([@bb0215]). There is a debate about its pathogenic role, since it was considered a harmless commensal parasite for many years. Nevertheless, recent studies demonstrated that it may induce disease with diverse symptoms. Such symptoms tend to improve in most cases with the elimination of the parasite by anti-parasitic treatment ([@bb0185]). Other studies reported that infection with *D. fragilis* could have a self-limiting character because patients improved without treatment ([@bb0195], [@bb0205]).

In the same line of evidence, there is a current discussion regarding the pathogenic mechanism of *D. fragilis* and its pathogenic role. It has been reported that *D. fragilis* causes colitis by an invasive ulcerative process. This conclusion was based on the discovery of numerous ulcers in the intestine of a female patient infected with *D. fragilis* ([@bb0170]). Furthermore, flat ulcerations together with acute and chronic inflammation, could be demonstrated in a biopsy taken from this patient. Another study showed that there were inflammatory changes in the mucosa of the rectum and sigmoid colon in *D. fragilis*-infected patients. In particular, superficial rounded infiltrations of cells in loosened stroma were observed, giving a picture of low-grade chronic proctitis ([@bb0155]). On the other hand, it was shown that multiplication of *D. fragilis* in the presence of suitable bacterial intestinal flora could cause disturbance of intestinal functions. It has been suggested that, the association of bacteria with *D. fragilis*, can develop amplified intestinal secretions, that may lead to the development of a suitable environment for the colonization by, and multiplication of *D. fragilis* ([@bb0120]).The present study was performed to study the infectivity and pathogenicity of *D. fragilis* and to determine the proper number of the parasite for experimental mice infection.

In this study, all mice orally inoculated with a high dose of 4 × 10^6^ of *D. fragilis* became infected. The infected mice showed loss of weight and diarrhea. This is in agreement with a previous study showing that mice infected with *D. fragilis* experienced an average weight loss of 2.38g (12%) compared with the control group ([@bb0140]).The presence or absence of symptoms associated with *D. fragilis* infection could be due to the presence of different genotypes of *D. fragilis*. This will be similar to what it has been described in other enteric protozoa, such as *G. lamblia* ([@bb0015]). An analysis of *D. fragilis* ribosomal genes proved the existence of two genetically distinct pathogenic and nonpathogenic variants ([@bb0105]). Nevertheless, only one *D. fragilis* genotype has been described in symptomatic and asymptomatic patients by several studies ([@bb0205], [@bb0110], [@bb0160]). Difference in parasitic load in the colon can also play a role, observing a dose depending onset of symptoms. When the number of protozoa exceeds this threshold, their pathogenic effect can be observed. So, in the presence of appropriate intestinal bacterial flora, a gradual physiologic change of the protozoan cell could cause a qualitative alteration of the parasite\'s enzyme activity. Theoretically, a higher parasitic DNA load would be expected in patients with more clinical symptoms compared to asymptomatic ([@bb0055]).

For a long time, it was thought that *D. fragilis* had no cyst stage and the parasite had only a trophozoite stage ([@bb0080], [@bb0150], [@bb0075]). In this study, examination of stool from infected mice showed trophozoite in its rounded form, which transformed into irregular forms after minutes in the MBD culture media. In addition, it was observed that the ingested rice starch was present in its cytoplasm. Moreover, a presumptive cyst stage with its characteristic appearance was present in infected mice feces. The cyst presented a distinct thick cyst wall, with a membranous, irregular inner cyst wall located directly adjacent to the encysted parasite, surrounded by a distinctive peritrophic space. These observations were in agreement with previous findings of cysts in animal models ([@bb0140]), as well as in human clinical samples ([@bb0190]).

Eida et al. reported that experimental infection of mice with *D. fragilis* resulted in histopathological changes in the caecum in the form of severe crypt hyperplasia, congestion, and edema of the lamina propria of caecal mucosa, and the interglandular epithelial cells were sloughed into the lumen. Moreover, there was penetration of multiple *D. fragilis* trophozoites in caecal glands ([@bb0060]). In the present study, the histopathological examination of the colon and caecum of mice in G2 showed spotty inflammation with hyperplasia in colonic glands while in heavily infected group G3 there was marked inflammatory infiltrate of mucosa and submucosa. The difference in the degree of inflammation between the two groups could be attributed to the inoculum doses used in the experiment, which means that *D. fragilis* infection is dose dependent and its pathogenic effect depends on the burden of the parasite on the large intestine, as suggested by [@bb0055]. In this study, no *D. fragilis* trophozoites were detected invading the colonic mucosa as previously observed in several studies describing lesions of the large intestine in the form of colitis ([@bb0170]), chronic or hemorrhagic proctitis ([@bb0155]) and appendicitis ([@bb0020], [@bb0200]), but no parasites were detected invading the underlying tissue. These pathogenic changes may be due to calprotectin release, which is a neutrophil protein, and its presence in the stool. This observation is indicative of neutrophilic infiltration into the gut lumen associated with inflammatory processes. Significantly elevated concentrations of fecal calprotectin have been demonstrated in the feces of infected mice experimentally infected with *D. fragilis* compared with the controls ([@bb0140]). Elevated fecal calprotectin has been reported in patients suffering from intestinal disorders such as inflammatory bowel disease (IBD) and inflammatory bowel syndrome (IBS) ([@bb0040]). *Dientamoeba* has also been incriminated as a possible cause of IBS ([@bb0185]). Some parasitic infections such as giardiasis ([@bb0095]) and intestinal schistosomiasis ([@bb0025]) showed similar elevated levels of calprotectin. Calprotectin is thought to induce inflammation through induction of pro-inflammatory chemokines, adhesion molecules and β~2~-integrin, thereby mediating leukocyte recruitment, adhesion, and trans-endothelial migration to inflamed tissue ([@bb0210], [@bb0065]). Moreover, the neutrophil migration and protein secretion causes epithelial damage or cell death (apoptosis), which leads to increased intestinal permeability and increased secretion of chloride ion, thus causing diarrhea in symptomatic patients ([@bb0115]).

In conclusion, this study revealed that large numbers of *D. fragilis* are needed for oral infection of mice. Despite its non-invasive nature, it can induce severe inflammation in the large intestinal mucosa if given in large doses. On the other hand, mice are considered a suitable animal model for *D. fragilis* experimental infection and this favors the study of the detailed biology and pathogenic mechanisms of this parasite. This is of great relevance to the advancement in the understanding of the pathology of this emerging parasite. This study suggests the presence of a cyst stage in the life cycle of *D. fragilis*. Further studies are recommended to evaluate the cyst infectivity to different lab animals and to study the ultrastructure of cysts, as well as the sequential changes of encystation through scanning and transmission EM.
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[^1]: Number of *D. fragilis* in 0.5 ml culture media.
